SciSparc Ltd. SPRC

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —$1.3M$2.9M$1.3M——————
SG&A —————$1.9M$2.5M$4.4M——
Operating income —-$7.3M-$6.8M-$8.3M-$5.8M-$3.3M-$4.1M-$7.2M-$5.8M-$2.0M
Net income —-$7.5M-$5.9M-$2.6M-$5.8M-$3.5M-$4.7M-$8.9M-$6.2M-$2.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets —$10.3M$11.2M$10.6M$9.9M$2.6M$1.2M$4.6M$9.6M$1.2M
Total equity —$8.9M$9.6M$6.4M$8.1M$1.4M$14.0K$77.0K$8.4M$573.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-091427.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Operating cash flow
  • Total equity
  • Total current assets
  • Property, plant and equipment
Operating cash flow, Total equity, Total current assets, Property, plant and equipment by fiscal year, in US dollars The same figures are in the table below this chart. 0 2.5M 5M 7.5M 10M Total equity, FY2016: 573K Total equity, FY2017: 8.4M Total equity, FY2018: 77K Total equity, FY2019: 14K Total equity, FY2020: 1.4M Total equity, FY2021: 8.1M Total equity, FY2022: 6.4M Total equity, FY2023: 9.6M Total equity, FY2024: 8.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow — — — — — — — — — —
Total equity $573.0K $8.4M $77.0K $14.0K $1.4M $8.1M $6.4M $9.6M $8.9M —
Total current assets — — — — — — — — — —
Property, plant and equipment — — — — — — — — — —

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
AKTX Akari Therapeutics Plc $1.79T — —
LLY ELI LILLY & Co $1.08T 50.1x 44.7%
JNJ JOHNSON & JOHNSON $663.28B 25.0x 6.0%
ONC BeOne Medicines Ltd. $529.55B 1,885.6x 40.2%
ABBV AbbVie Inc. $453.19B 108.7x 8.6%
MRK Merck & Co., Inc. $370.89B 20.6x 1.3%
ABT ABBOTT LABORATORIES $188.69B 29.1x 5.7%
PFE PFIZER INC $162.16B 20.9x -1.6%